



ASX Announcement

Form 10 Registration Statement

Sydney, Australia and Eden Prairie, MN: 4 October 2011 – Sunshine Heart, Inc. (ASX: SHC) (**Sunshine Heart**) filed a general form for registration of securities on Form 10 with the United States Securities Exchange Commission (**SEC**) on 30 September 2011. A copy of the Form 10 is attached.

Sunshine Heart has filed the Form 10 with the SEC in order to register its shares of common stock under section 12(b) of the US Securities Exchange Act of 1934, as amended (**Exchange Act**). The filing of the Form 10 is also one of the steps towards Sunshine Heart's listing on the Nasdaq Capital Market. Sunshine Heart will maintain its ASX listing.

The Form 10 is now subject to a period of review and comment by the SEC. Sunshine Heart will respond to any comments received by the SEC and progressively modify the Form 10 in response to the SEC's comments. All SEC comments and each iteration of the Form 10 will be available at <http://www.sec.gov/edgar.shtml>.

Once Sunshine Heart's shares of common stock have been registered with the SEC, Sunshine Heart will be subject to the reporting requirements of the Exchange Act, which will require Sunshine Heart to file United States annual reports, quarterly reports and other reports, and will be required to comply with all other applicable obligations of the Exchange Act.

About the C-Pulse Heart Assist System

C-Pulse Heart Assist System utilizes the proven scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Operating outside the patient's bloodstream, the novel extra-aortic approach of the C-Pulse technology offers greater flexibility allowing patients to disconnect as necessary or desired. The C-Pulse Heart Assist's potential benefits may help reverse the heart failure process or maintain the patient's current condition, thereby preventing the need for later stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants.

About Sunshine Heart

Sunshine Heart (ASX: SHC) is a global medical device company committed to novel cardiac and coronary therapy. The company is currently developing the C-Pulse[®] Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology by enabling an increase in cardiac output, an increase in coronary blood flow, and a reduction in the heart's pumping load. The company has received approval from the U.S. Food and Drug Administration to conduct a U.S. feasibility clinical trial with the C-Pulse System. Sunshine Heart is a Delaware-based corporation headquartered in Minneapolis, MN, with a subsidiary presence in Australia. The company has been listed on the Australian Securities Exchange (ASX) since September 2004. For more information, please visit www.sunshineheart.com.

For further information, please contact:

Dave Rosa

Chief Executive Officer

+1 952 345 4200

Jeff Mathiesen

Chief Financial Officer

+1 952 345 4200